ライフサイエンスコーパス: in-stent

1 as associated with a greater late lumen loss in stent and more frequent angiographic restenosis regar

2 vascular injury and is a prominent component in stented and nonstented restenotic lesions.

3 The 30-day MACCE rates were 3.7% and 1.5% in stented and unstented patients, respectively (p < 0.0

4 are addressed, including novel developments in stents and stent coatings, conventional drugs, nuclei

5 ivalent, we defined the relationship between in-stent and analysis segment late loss, the shape of th

6 sions showed similar vessel response in both in-stent and reference segments regardless of the DES ty

7 The final in-stent angiographic minimum lumen diameter was 2.99+/-

8 Secondary outcomes included final in-stent angiographic minimum lumen diameter, procedure

9 as included use of new metal alloys, changes in stent architecture, and use of bioresorbable polymers

10 In stented arteries, there was an increase in intima-med

11 g rapid and stable cell homing and expansion in stented arteries.

12 was assumed, late loss accurately estimated in-stent binary angiographic restenosis for the control

13 (0.6 +/- 0.5 mm vs. 0.7 +/- 0.5 mm; p = NS), in-stent binary restenosis (7.1% vs. 6.9%; p = NS), in-s

14 Secondary endpoints were in-stent binary restenosis, major adverse cardiac events

15 d MNPs to achieve site-specific transduction in stented blood vessels.

16 ta-analysis that accounted for the variation in stent choice.

17 nd progression of neointimal hyperplasia and in-stent clotting.

18 After successful demonstration, in-stent coronary thrombosis was induced by x-ray-guided

19 The composition of the in-stent ECM has not been well characterized in humans.

20 ificant advances have also occurred recently in stent graft research and development.

21 use, and highlights the recent developments in stent graft treatment of abdominal aortic aneurysms.

22 In stent-implanted vessels, real-time imaging illuminate

23 The primary endpoint of in-stent (in-balloon) late loss was significantly less w

24 endpoint was noninferiority of angiographic in-stent (in-balloon) late loss with a delta of 0.25 mm.

25 o model of SM cell (SMC) differentiation and in stent-induced pig coronary vessel injury.

26 of preinterventional arterial remodeling on in-stent intimal hyperplasia (IH) after implantation of

27 In-stent late loss at 9 months was 0.29+/-0.60 versus 0.

28 The primary end point was in-stent late loss at 9 months.

29 The primary end point was in-stent late loss at 9-month angiographic follow-up (no

30 The observed difference in in-stent late loss between both groups was -0.16 mm (95%

31 In the sirolimus-eluting stent arm, in-stent late loss correlated better with target-lesion

32 he primary angiographic endpoint was 6-month in-stent late loss measured by quantitative coronary ang

33 We hypothesized that mean in-stent late loss might be a more stable estimator of r

34 The mean in-stent late loss observed in the SIRIUS trial was 0.17

35 with an acute gain of 1.41 mm (0.46 mm) and in-stent late loss of 1.08 mm (0.49 mm).

36 The 6-month in-stent late loss was 0.15 +/- 0.34 mm for PROMUS Eleme

37 of reference vessel diameter on TLR than on in-stent late loss.

38 Primary endpoint was 6-month angiographic in-stent late lumen loss (LLL) within a noninferiority s

39 found noninferior for the primary end point in-stent late lumen loss at 9 months.

40 nt (X-EES) in terms of the primary end point in-stent late lumen loss at 9 months.

41 luting stent, P=0.75); 13-month angiographic in-stent late lumen loss was 0.22+/-0.41 mm and 0.23+/-0

42 he primary endpoint was 6-month angiographic in-stent late-luminal loss.

43 In the post-transplant patients, in-stent LL was closely coupled to control segment LL (R

44 n de novo lesions showed significantly lower in-stent LLL at 6 months than the Taxus Liberte stent di

45 In-stent LLL was significantly lower in Cre8 group (0.14

46 In-stent LLL was similar between patients treated with B

47 Visualization of the in-stent lumen at CT angiography with a 16-detector row

48 Mean in-stent lumen loss was 0.90 +/- 0.59 mm for PF-PES and

49 Estimated values for in-stent luminal diameter were lower with CT than with c

50 computed tomographic (CT) measurement of the in-stent luminal diameter.

51 rotrusion (hazard ratio [HR], 2.35; P<0.01), in-stent minimum lumen area (MLA) <4.5 mm(2) (HR, 2.72;

52 nfarction was associated with a larger final in-stent minimum lumen diameter.

53 se in PA gradient or post-procedure ratio of in-stent minimum to pre-stent distal diameter >80%.

54 polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent a

55 es injection concurrent with injury, reduces in-stent neointimal formation and arterial stenosis in h

56 ulated bisphosphonates inhibits experimental in-stent neointimal formation.

57 limus treatment groups significantly reduced in-stent neointimal growth (46% reduction and 42% reduct

58 de of the same family as sirolimus) inhibits in-stent neointimal growth in rabbit iliac arteries.

59 Oral everolimus suppresses in-stent neointimal growth in the rabbit iliac artery.

60 mbination with dexamethasone (DEX) to reduce in-stent neointimal hyperplasia.

61 ility of drug-eluting stents has reduced the in-stent neointimal proliferation that causes restenosis

62 In-stent noise, signal-to-noise ratio(SNR), stent-lumen

63 , SAFIRE was superior to FBP with regards to in-stent noise, SNR, SAIR, and image quality score.

64 r, no patients showed clinically significant in-stent or edge restenosis (diameter stenosis >/=50%) d

65 ediate and impressive, 14 patients developed in-stent or in-segment restenosis, requiring repeated in

66 thods will be required to decrease recurrent in-stent or in-segment restenosis.

67 Urinary tract infections were more common in stented patients (RR 1.49), unless the patients were

68 ns of Non-Adherence to Anti-Platelet Regimen in Stented Patients [PARIS]; NCT00998127).

69 s of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry), 4222 patients who underwe

70 s of non-adherence to anti-platelet regimens in stented patients) registry is a prospective observati

71 ns of Non-Adherence to Anti-Platelet Regimen in Stented Patients) registry, separate risk scores were

72 In stented patients, an antibiotic with anti-enterococca

73 The 13-month angiographic in-stent percent diameter stenosis amounted to 12.0 +/-

74 primary prespecified IVUS end point was the in-stent percent net volume obstruction at follow-up.

75 The primary prespecified end point was the in-stent percent net volume obstruction at follow-up.

76 t binary restenosis (7.1% vs. 6.9%; p = NS), in-stent percent volume obstruction by IVUS (29% vs. 24%

77 In stented pig coronary vessels, LPP was expressed in th

78 y using a Rotarex system followed by a stent-in-stent placement procedure.

79 d to fully study this issue; and 5) advances in stent platforms for drug elution as well as adjunctiv

80 EC p-S6RP expression in stented porcine arteries confirmed our in vitro findi

81 no data on the feasibility and safety of RDN in stented RA.

82 -magnetic delivery conditions, were observed in stented rat carotid arteries.

83 in the PEB group and also in subgroups with in-stent restenosis >10 mm (0.05 versus 0.26 mm; P=0.000

84 e plaque prolapse (2 cases); and (5) diffuse in-stent restenosis (1 case).

85 y-verified NA was observed in 40 stents with in-stent restenosis (62%), was more prevalent in DES tha

86 s of the stented segment without significant in-stent restenosis (71%).

87 a intracoronary radiation therapy (ICRT) for in-stent restenosis (IRS).

88 ic, and histological features of concomitant in-stent restenosis (ISR) and cardiac allograft vasculop

89 aneous treatment of drug-eluting stent (DES) in-stent restenosis (ISR) and the correlates for recurre

90 Recent successes in the treatment of in-stent restenosis (ISR) by drug-eluting stents belie t

91 As a result, in-stent restenosis (ISR) has become a widespread proble

92 for bare metal stent and drug-eluting stent in-stent restenosis (ISR) have not been established.

93 Re-stenting of in-stent restenosis (ISR) improves acute angiographic re

94 Clinical presentation of bare metal stent in-stent restenosis (ISR) in patients undergoing target

95 In-stent restenosis (ISR) is a novel pathobiologic proce

96 nt of patients with drug-eluting stent (DES) in-stent restenosis (ISR) is more challenging than that

97 Treatment of in-stent restenosis (ISR) is still challenging.

98 ry gamma-irradiation in preventing recurrent in-stent restenosis (ISR) is well established.

99 It is unclear whether PCI of in-stent restenosis (ISR) lesions in degenerated SVGs is

100 ual distribution of gamma radiation in human in-stent restenosis (ISR) lesions, and 2) to analyze the

101 ectomy for de novo atherosclerosis (n=55) or in-stent restenosis (ISR) of a bare metal stent (n=34).

102 outcomes of patients who developed coronary in-stent restenosis (ISR) or stent thrombosis (STH) insi

103 percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) randomized to short (6 months)

104 In-stent restenosis (ISR) remains a difficult problem in

105 nt of patients with drug-eluting stent (DES) in-stent restenosis (ISR) remains a major challenge.

106 Management of patients with in-stent restenosis (ISR) remains an important clinical

107 examined long-term outcomes of patients with in-stent restenosis (ISR) who underwent different percut

108 s in 66 patients with native coronary artery in-stent restenosis (ISR) who were treated with (192)Ir

109 phic angiography (CTA) and their relation to in-stent restenosis (ISR), stent fracture (SF), and over

110 x lesions also introduced a new problem: DES in-stent restenosis (ISR), which occurs in 3% to 20% of

111 cted distal left main coronary artery (UDLM) in-stent restenosis (ISR).

112 luting stent (SES) implantation treatment of in-stent restenosis (ISR).

113 ary radiation therapy (IRT) in patients with in-stent restenosis (ISR).

114 erapy (IRT) is the only proven treatment for in-stent restenosis (ISR).

115 ts of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR).

116 radiation therapy (IRT) for the treatment of in-stent restenosis (ISR).

117 tion therapy (IRT) in diabetic patients with in-stent restenosis (ISR).

118 racoronary gamma-radiation reduces recurrent in-stent restenosis (ISR).

119 tion of intracoronary irradiation to prevent in-stent restenosis (ISR).

120 ntages over other modalities in treatment of in-stent restenosis (ISR).

121 ES) in patients with bare-metal stents (BMS) in-stent restenosis (ISR).

122 EES in patients with bare-metal stents (BMS) in-stent restenosis (ISR).

123 intervention (PCI) can lead to a decrease in in-stent restenosis (ISR).

124 reatment of superficial femoral artery (SFA) in-stent restenosis (ISR).

125 ee events were potentially related to BVS: 1 in-stent restenosis (treated 7 months after pPCI with dr

126 adiation for the prevention of recurrence of in-stent restenosis achieved similar rates of restenosis

127 f the main events responsible for bare metal in-stent restenosis after percutaneous coronary interven

128 lular composition of human coronary arterial in-stent restenosis after various periods of time follow

129 dary end points were the incidence of binary in-stent restenosis and 12-month major adverse cardiac e

130 stent fracture rate and its association with in-stent restenosis and adverse outcomes in the ACT-1 tr

131 ailure and in those undergoing treatment for in-stent restenosis and bifurcations.

132 In-stent restenosis and bypass graft failure are charact

133 een patients with superficial femoral artery in-stent restenosis and chronic limb ischemia were recru

134 ed release of NO donor significantly reduces in-stent restenosis and is associated with increase in v

135 metal stents associates with a high risk of in-stent restenosis and need for future revascularizatio

136 y appear to be associated with high rates of in-stent restenosis and repeat target lesion revasculari

137 Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target v

138 lular matrix (ECM) remodeling contributes to in-stent restenosis and thrombosis.

139 nts with recurrent symptoms had angiographic in-stent restenosis and were successfully revascularized

140 Native atherosclerosis and in-stent restenosis are focal and evolve independently.

141 e success of irradiation (brachytherapy) for in-stent restenosis argues that DNA-damage p53 responses

142 apy, renal failure, bifurcation lesions, and in-stent restenosis as significant correlates of ST (P<0

143 The primary end point of recurrent in-stent restenosis assessed by ultrasound at 6 months w

144 erior descending artery, length > or =20 mm, in-stent restenosis at baseline, and use of rotablator.

145 considerable reduction in the development of in-stent restenosis at the cost of an increased risk of

146 Five of the 11 patients had previous in-stent restenosis before CABG.

147 Gene therapy to treat in-stent restenosis by using gene vector delivery from t

148 trasound (IVUS) analysis was performed in 30 in-stent restenosis cases treated with a 40-mm (90)Sr/Y

149 Unfortunately, in-stent restenosis continues to plague this procedure,

150 iabetics are at increased risk of developing in-stent restenosis for unclear reasons.

151 In-stent restenosis has a high recurrence rate after per

152 he Gamma-1 trial, coronary brachytherapy for in-stent restenosis improved clinical outcomes but incre

153 adiation for the prevention of recurrence of in-stent restenosis in native coronaries and saphenous v

154 A total of 120 patients with diffuse in-stent restenosis in native coronary arteries (lesion

155 gamma-radiation therapy for the treatment of in-stent restenosis in patients with bypass grafts.

156 ding stents is associated with high rates of in-stent restenosis in patients with diabetes mellitus.

157 myocardial CTP improves diagnosis of CAD and in-stent restenosis in patients with stents compared wit

158 A total of 120 patients with in-stent restenosis in saphenous-vein grafts, the majori

159 al novel therapeutic approach for inhibiting in-stent restenosis in such patients.

160 nalysis, ACS was an independent predictor of in-stent restenosis in the cohort treated with bare-meta

161 In-stent restenosis is a major limitation of intracorona

162 DCBA for superficial femoral artery in-stent restenosis is associated with less recurrent re

163 Furthermore, if the capacity of DES to treat in-stent restenosis is confirmed in randomized trials, t

164 the past few years, it has become clear that in-stent restenosis is largely due to the migration and

165 confidence interval, 0.98-12.20; P=0.05) and in-stent restenosis lesions (odds ratio, 5.30; 95% confi

166 ion protocol of (90)Sr/Y radiation to native in-stent restenosis lesions may provide substantial inhi

167 1025 consecutive native coronary artery, non-in-stent restenosis lesions undergoing PCI, 72 hematomas

168 th treatment of chronic total occlusions and in-stent restenosis lesions, and had higher 12-month maj

169 More careful consideration of the type of in-stent restenosis may aid in identifying when alternat

170 Balloon angioplasty of in-stent restenosis may, therefore, fail due to ECM chan

171 % in drug-eluting stents, with mean diameter in-stent restenosis of 36% and 8%, respectively.

172 nity-based institutions in 396 patients with in-stent restenosis of a previously implanted bare-metal

173 travascular gamma radiation in patients with in-stent restenosis of saphenous-vein bypass grafts.

174 The binary in-stent restenosis rate was 2% for the sirolimus stent

175 ion in circulating lymphocytes and increased in-stent restenosis risk (OR, 1.43; 95% CI, 1.00-1.823;

176 rom normal vessels (n-VSMCs) and angioplasty/in-stent restenosis sites (r-VSMCs).

177 a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well

178 The Washington Radiation for In-Stent Restenosis Trial (WRIST) PLUS, which involved 6

179 R patients from the Washington Radiation for In-Stent restenosis Trial (WRIST) that met the following

180 rachytherapy in the Washington Radiation for In-Stent Restenosis Trial (WRIST).

181 ere enrolled in the Washington Radiation for In-Stent Restenosis Trial (WRIST; ISR length, 10 to 47 m

182 The Washington Radiation for In-Stent Restenosis Trial for long lesions (Long WRIST)

183 The Washington Radiation for In-Stent Restenosis Trial is a double-blinded randomized

184 ery ISR from WRIST (Washington Radiation for In-Stent Restenosis Trial) and 31 patients with SVG ISR

185 lled in (1) Long WRIST (Washington Radiation In-Stent Restenosis Trial), a double-blind, placebo-cont

186 In the Washington Radiation for In-Stent Restenosis Trial, patients with ISR treated wit

187 332 patients with in-stent restenosis underwent successful coronary interv

188 In-stent restenosis was 0 in the proximal LAD sirolimus-

189 In-stent restenosis was defined as a stent area stenosis

190 Underlying in-stent restenosis was present in only 4 (31%) of 13 ca

191 cember 1997 and July 1998, 252 patients with in-stent restenosis were randomized to receive brachythe

192 by offering reserve coronary circulation, if in-stent restenosis were to occur in the treated left ma

193 enter, randomized trial of 384 patients with in-stent restenosis who were enrolled between February 2

194 ic choice for patients with complex, diffuse in-stent restenosis who would otherwise have a very poor

195 ly performed, the prevalence of renal artery in-stent restenosis will increase.

196 fect resulted in a significant inhibition of in-stent restenosis with a relatively low dose of MNP-en

197 (PEPCAD DES-Treatment of DES-In-Stent Restenosis With SeQuent(R) Please Paclitaxel El

198 urrent restenotic lesion, after treatment of in-stent restenosis with vascular brachytherapy in the W

199 crog/mm2, reduced angiographic indicators of in-stent restenosis without short- or medium-term side e

200 (bifurcations, chronic total occlusions, and in-stent restenosis).

201 After successful catheter-based treatment of in-stent restenosis, 476 patients were randomly assigned

202 s coronary dissection, no reflow phenomenon, in-stent restenosis, and stent thrombosis requires accur

203 to be effective in the treatment of coronary in-stent restenosis, but data are limited regarding thei

204 Drug-eluting stents reduce the incidence of in-stent restenosis, but they result in delayed arterial

205 ibitors, including atherothrombotic disease, in-stent restenosis, heart failure, and sepsis.

206 Although MSA is a consistent predictor of in-stent restenosis, its predictive value in BMS is stil

207 ever, arterial reobstruction after stenting, in-stent restenosis, remains an important problem.

208 For in-stent restenosis, the benefit of DCBA over POBA remai

209 After conventional treatment of in-stent restenosis, the incidence of recurrent clinical

210 ail" (192)Ir intracoronary brachytherapy for in-stent restenosis, treatment with (192)Ir delays the t

211 ted to dramatically reduce the recurrence of in-stent restenosis, up to 24% of these patients will st

212 egy against vaso-occlusive disorders such as in-stent restenosis, vein-graft stenosis, and transplant

213 ent thrombosis-related MI (n=63; 24.0%), and in-stent restenosis-related MI (n=58; 22.1%).

214 rug-eluting stents has decreased the rate of in-stent restenosis.

215 ive in reducing neointimal proliferation and in-stent restenosis.

216 ntrolled targeting of MNPs with efficacy for in-stent restenosis.

217 obstruction post stenting, a disorder termed in-stent restenosis.

218 clinically on drug-eluting stents to inhibit in-stent restenosis.

219 efficacy in limiting recurrence of existing in-stent restenosis.

220 tomotic device stenosis, possibly similar to in-stent restenosis.

221 tive alternative to VBT for the treatment of in-stent restenosis.

222 y supersede VBT as the therapy of choice for in-stent restenosis.

223 in the stented main branch that can lead to in-stent restenosis.

224 lusions, planned two-stent bifurcations, and in-stent restenosis.

225 use of a stent to deliver a drug may reduce in-stent restenosis.

226 iction of progression of atherosclerosis and in-stent restenosis.

227 r brachytherapy for the treatment of diffuse in-stent restenosis.

228 ESS may have a limited role in in-stent restenosis.

229 the rate of recurrent restenosis in diffuse in-stent restenosis.

230 a 90Sr/90Y beta-source for the treatment of in-stent restenosis.

231 in patients undergoing treatment for diffuse in-stent restenosis.

232 nary radiation therapy reduces recurrence of in-stent restenosis.

233 seful adjunct for the clinical prevention of in-stent restenosis.

234 e for preventing recurrence in patients with in-stent restenosis.

235 giographic outcomes of patients with diffuse in-stent restenosis.

236 hought to be important for coronary arterial in-stent restenosis.

237 bo after interventional treatment of diffuse in-stent restenosis.

238 ogical data on the morphological features of in-stent restenosis.

239 percutaneous coronary intervention (PCI) for in-stent restenosis.

240 proliferation contribute to later stages of in-stent restenosis.

241 temic delivery nanoparticle PXL for reducing in-stent restenosis.

242 racoronary gamma-radiation reduces recurrent in-stent restenosis.

243 adiation for the prevention of recurrence of in-stent restenosis.

244 delaying, although probably not preventing, in-stent restenosis.

245 ciated with major adverse clinical events or in-stent restenosis.

246 ere used to investigate the role of miRNA in in-stent restenosis.

247 f saphenous vein grafts, ostial lesions, and in-stent restenosis.

248 lates cell proliferation, a key component of in-stent restenosis.

249 , rs350104, and rs164390 affects the risk of in-stent restenosis.

250 y, saphenous vein grafts, ostial lesions, or in-stent restenosis.

251 e as useful tools in risk stratification for in-stent restenosis.

252 tents) consecutive symptomatic patients with in-stent restenosis.

253 %) could be attributed to segments with >70% in-stent restenosis.

254 nts has demonstrated efficacy for preventing in-stent restenosis; however, both the inflammatory effe

255 smoker, multivessel disease, treatment of an in-stent restenotic lesion), laboratory findings (low ba

256 Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting sten

257 treatment group included 68 patients with 74 in-stent restenotic lesions.

258 We analyzed 29 coronary arterial in-stent restenotic tissue samples (14 left anterior des

259 Changes in stent section shape after balloon deflation are impor

260 ut gap), and V (with transection causing gap in stent segment).

261 p-ERK/p-Akt ratio in stented segments uniquely correlated with neointimal

262 stance and diabetes on Akt and ERK signaling in stented segments.

263 d ratio, 0.32; P=0.015) and from significant in-stent stenosis (hazard ratio, 0.14; P=0.002).

264 s included stent migration (one patient) and in-stent stenosis (three patients).

265 No significant focal in-stent stenosis analyzed with angiography (percentage

266 sociation studies of human neointima-induced in-stent stenosis confirmed the association of the ROS1

267 on was documented in 9 cases and significant in-stent stenosis in 17 cases.

268 y is effective in reducing the recurrence of in-stent stenosis in native coronary arteries.

269 lantation to intravascular brachytherapy for in-stent stenosis of bare metal stents.

270 The role of intravascular brachytherapy for in-stent stenosis of drug eluting stents is very much in

271 Even with in-stent stenosis, the role of intravascular brachythera

272 from a stent platform significantly reduced in-stent stenosis, while promoting re-endothelialization

273 is already decreasing the clinical impact of in-stent stenosis.

274 01), resulting in a 50% reduction of percent in-stent stenosis.

275 owed restriction of growth within an area of in-stent stenosis.

276 Current innovations in stent technologies, including biodegradable stents, n

277 role of cholangioscopy, and recent advances in stent technology are reviewed.

278 remains a clinical problem despite advances in stent technology in both bare-metal and drug-eluting

279 In-stent thin-cap neoatheroma is more prevalent, is dist

280 In-stent thrombi: in-stent thrombosis was observed in al

281 f rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary s

282 on DES entails a tradeoff between reductions in stent thrombosis and MI and increases in major hemorr

283 xaban 2.5 mg was associated with a reduction in stent thrombosis and mortality.

284 There were no significant differences in stent thrombosis or bleeding complications.

285 The reduction in stent thrombosis with ticagrelor was numerically grea

286 VUS guidance was associated with a reduction in stent thrombosis, myocardial infarction, and major ad

287 s, which is relevant to reports of very late in-stent thrombosis at altitude.

288 l applications include detection of coronary in-stent thrombosis or thrombus burden in patients with

289 Both of these patients developed acute in-stent thrombosis postoperatively (days 5 and 2) despi

290 feasibility of MRI of coronary thrombus and in-stent thrombosis using a novel fibrin-binding molecul

291 In-stent thrombi: in-stent thrombosis was observed in all stents after EP-

292 , inflammatory response, and mechanism(s) of in-stent thrombosis were assessed.

293 ion is essential for the prevention of early in-stent thrombosis, but clopidogrel use among older DES

294 ar medicine include clopidogrel and risk for in-stent thrombosis, steady-state warfarin dose, myotoxi

295 ), in a swine model of coronary thrombus and in-stent thrombosis.

296 Endoleaks and in-stent thrombus of thoracic aorta were detectable to 1

297 ties in each vessel, as well as the ratio of in-stent to PV flow, were compared before and after TIPS

298 Ureteral complication rate was 1.9% in stent versus 5.8% in no-stent group (P=0.007).

299 The adjacent wall stresses were very minimal in stents with 180/100 and 70/70 mum struts after embedd

300 flammatory cell content was 2.4-fold greater in stents with restenosis versus no restenosis, and infl